BRIEF-Alumis And Kaken Pharmaceutical Announce Collaboration And Licensing Agreement For ESK-001 In Dermatology In Japan

Reuters
25 Mar
BRIEF-Alumis And Kaken Pharmaceutical Announce Collaboration And Licensing Agreement For ESK-001 In Dermatology In Japan

March 25 (Reuters) - Alumis Inc ALMS.O:

  • ALUMIS AND KAKEN PHARMACEUTICAL ANNOUNCE COLLABORATION AND LICENSING AGREEMENT FOR ESK-001 IN DERMATOLOGY IN JAPAN

  • ALUMIS INC - TO RECEIVE $40 MILLION UPFRONT, POTENTIAL $140 MILLION IN MILESTONE PAYMENTS

Source text: ID:nGNX1yGWLl

Further company coverage: ALMS.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10